K
KMSTF
vs
S&P 500
S&P 500
Over the past 12 months, KMSTF has underperformed S&P 500, delivering a return of -61% compared to the S&P 500's +14% growth.
Stocks Performance
KMSTF vs S&P 500
Performance Gap
KMSTF vs S&P 500
Performance By Year
KMSTF vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Kadimastem Ltd
Glance View
Kadimastem Ltd. is a clinical-stage bio-pharmaceutical company engaging in the development of industrial regenerative medicine therapies based on differentiated cells derived from Human Embryonic Stem Cells to treat neurology-degenerative diseases. The Company’s technology enables the differentiation of stem cells into insulin secreting beta cells, as well as a range of neural cells (including Oligodendrocytes, Astrocytes). The firm produces islet-like clusters that show glucose-stimulated insulin secretion. In addition, the Company is partnering with pharmaceutical companies interested to screen potential drug compounds (hit-lead, lead optimization) on its stem-cell derived cells, primarily oligodendrocytes and astrocytes.
